2 women shot while trying to break up fight at Koeneman Park
ST. LOUIS COUNTY, Mo. – A University City woman has been charged for shooting two women who attempted to break up a fight at Koeneman Park.
According to Mary Schmitt, a spokeswoman, the shooting happened around 6:05 p.m. on Saturday, May 30, in the 2600 block of Shannon Avenue in Jennings.
Police said the two victims attempted to break up a fight between two other people. In response, Imani R. Easley, 23, pulled out a Glock pistol and shot one victim in her right arm and the other victim in her chest.
Both victims were rushed to the hospital for medical treatment. The woman who was shot in her chest remains listed in critical condition.
Body cam video reveals new details in viral North County K-9 incident
Police said there were several bystanders and witnesses to the shooting, and the entire incident was captured on Facebook video.
After reviewing the video, police arrested Easley. Police said Easley later admitted to shooting both victims.
The St. Louis County Prosecuting Attorney's Office charged Easley with two counts of first-degree assault, two counts of armed criminal action, and one count of unlawful use of a weapon. Easley remains jailed on a $500,000 cash-only bond. She has a bond reduction hearing scheduled for June 9, followed by a preliminary hearing on July 2.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study
SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 ( that further validates the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating osteoarthritis (OA) pain. Professor Saoirse O'Sullivan, Vice President of Translation Sciences at Artelo Biosciences, presented results from an animal study titled: 'The Fatty Acid Binding Protein 5 Inhibitor ART26.12 is a Novel Analgesic for Osteoarthritis Pain.' The data builds upon an extensive set of pre-clinical data for ART26.12 that demonstrates analgesic and anti-nocicpetive effects in multiple models of pain. Positive effects of ART26.12 were observed in a surgical rat model of osteoarthritis, in which either single or repeated oral doses of Artelo's FABP5 inbitor increased the ability of rats to bear weight on the limb with OA out to four weeks. Professor O'Sullivan stated, 'ART26.12 was effective in a dose-responsive manner, with sustained and consistent effects over 28 days. The analgesic effect of ART26.12 was similar to naproxen, a proven first-line therapy which is often hampered by a number of serious side effects when taken chronically.' Now undergoing human trials, ART26.12 is a novel, non-opioid, non-steroidal drug candidate initially in development for the prevention and treatment of peripheral neuropathy caused by common chemotherapy treatments with potential for development as an alternative for chronic OA pain. OA is a progressive joint disease in which cartilage wears away over time, causing chronic pain, stiffness, swelling, and significant loss of mobility, especially in the knees, hips, hands, and spine. It affects approximately 606.9 million people globally, including over 32 million in the U.S., and can lead to disabling pain, reduced quality of life, and loss of independence, especially in advanced cases. About ART26.12 ART26.12, Artelo's lead FABP5 inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. Data from the first Phase 1 trial with ART26.12 is anticipated in Q2 2025. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in several pathologies. In addition to ART26.12 in CIPN, Artelo's extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders. About Artelo Biosciences Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at and X: @ArteloBio. Forward Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, efficacy of the Company's product candidates, results and conclusions from preclinical studies and clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, 'expect,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'estimate,' 'potential,' 'predict,' 'project,' 'should,' 'would' and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws. Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: ARTL@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
28 minutes ago
- Business Upturn
Foldax Secures Approval for TRIA Mitral Heart Valve in India
SALT LAKE CITY, Utah, United States: Foldax® Inc., a leader in heart valve innovation, today announced that the Indian Central Drugs Standard Control Organization (CDSCO) approved its TRIA™ Mitral Valve. Dolphin Life Science India LLP will locally manufacture the TRIA Mitral Valve in India. This press release features multimedia. View the full release here: The TRIA Mitral Valve is made from proprietary LifePolymer material, developed specifically for heart valve use and engineered at a molecular level to be calcium-resistant, biostable and biocompatible. The valves are robotically manufactured for precision and consistency at scale. Traditional valves made from animal tissue are prone to calcification and degradation, limiting their durability and often leading to repeat surgeries, especially for younger patients. Mechanical valves, while durable, are prone to thrombosis and require lifelong anticoagulation therapy that can impact a patient's long-term quality of life. Foldax's vision for its novel polymer heart valves is to address the limitations of tissue and mechanical valves by making them durable, with the goal of avoiding the requirement for lifelong anticoagulation. The company's portfolio of valves in development (transcatheter and surgical), including robotic implantation capabilities, is based on its proprietary LifePolymer™, a polymer material developed specifically for heart valve use and engineered at a molecular level to be calcium-resistant, biostable, and biocompatible. All Foldax valves are robotically manufactured for precision and consistency at scale. Clinical research on the TRIA Mitral Valve demonstrates favorable safety, stable hemodynamics, and meaningful improvements in patient quality of life.1 'My experience with the TRIA Mitral Valve has shown me that there is now a compelling alternative for a diverse patient population, including those as young as 18 years old and women of childbearing age, many of whom suffer from mitral valve damage caused by rheumatic fever,' said Kaushal Pandey, MD, Principal Investigator of the TRIA Mitral Valve India clinical trial and Cardiac Surgeon at P.D. Hinduja Hospital in Mumbai. 'Gaining approval with our partner Dolphin Life Sciences for the world's first polymer heart valve marks a defining moment in the evolution of heart valve therapy and disrupts long-standing paradigms in the heart valve industry,' said Ken Charhut, Executive Chairman and CEO of Foldax. 'We intend to extend our unique platform utilizing LifePolymer material and proprietary robotic manufacturing into additional applications in transcatheter devices and other valve positions. We look forward to making a transformative impact in India and other geographies where we can fill critical unmet clinical needs.' *The TRIA Mitral Valve is for investigational use only and is not available for commercial sale in the U.S. About Foldax Headquartered in Salt Lake City, Utah, Foldax is reinventing every aspect of the heart valve – from material to design to manufacturing – to develop surgical and transcatheter valves with the potential to last a lifetime, addressing limitations of tissue and mechanical valves. Foldax investors include Angel Physicians Fund, Biostar Capital, Caltech, Glenview Capital, Kairos Ventures, Memorial Care Innovation Fund and Sayan Bioventures. For more information on the TRIA Mitral Valve and Foldax's commitment to revolutionizing heart valve care, visit . References: Isaac George, MD. Surgical Mitral Valve Replacement with a Novel Polymeric Valve: 30-Day Results from an Indian Clinical Study of the Foldax TRIA Valve. Presented at New York Valves: The Structural Summit, June 5-7, 2024, New York, New York. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Yahoo
29 minutes ago
- Yahoo
North Lima man now facing charges in fatal crash
GIRARD, Ohio (WKBN) – A North Lima man answered to charges in a fatal crash last November. Joshua Johnston, 37, is charged with aggravated vehicular homicide, a third-degree felony, and vehicular assault, a fourth-degree felony, as well as failure to yield and a seatbelt violation. Charges against Joshua Johnston were filed March 26 in Girard Municipal Court, and he was arraigned on Wednesday. Johnston was driving a 2017 Ford Fusion southbound on Warner Road on Nov. 10, 2024, when he failed to yield to a 2022 Subaru Crosstrek traveling eastbound on state Route 82, according to a report from the Ohio State Highway Patrol. The force of the crash pushed the Fusion off the road and into a ditch. A passenger, Miranda Zullo, 35 of Youngstown, was pronounced dead at the scene. Another passenger, 13-year-old Myle Johnston from Struthers, was transported to the hospital with serious injuries. She has since been released from the ICU, and her mother said she is doing much better. Johnston has been incarcerated at the Belmont Correctional Institution after he was sentenced in December to a year in prison for breaking into the Smith Township home of his ex-girlfriend. He is set to be released from prison on November 17. Johnston is set to appear in court again for a preliminary hearing in his crash case on July 2. Kristen Hephner and Joe Gorman contributed to this report. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
